1-苯基-1-环己羧酸 | 1135-67-7

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苯基-1-环己羧酸
• 中文别名: 1-苯基环己烷羧酸
• 英文名称: 1-phenyl-cyclohexanecarboxylic acid
• 英文别名: 1-phenylcyclohexane-1-carboxylic acid；1-phenyl-1-cyclohexanecarboxylic acid；1-phenyl-1-cyclohexyl carboxylic acid；1-Phenylcyclohexanecarboxylic acid
• CAS: 1135-67-7
• 化学式: C₁₃H₁₆O₂
• 分子量: 204.269
• InChiKey: QXXHHHWXFHPNOS-UHFFFAOYSA-N

物化性质

• 熔点：
  119-124 °C
• 沸点：
  302.76°C (rough estimate)
• 密度：
  1.0404 (rough estimate)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会发生分解，没有已知的危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将贮藏器密封，并存放在阴凉、干燥处。确保工作环境具有良好的通风或排气设施。

SDS

Name:	1-Phenyl-1-cyclohexanecarboxylic acid 95% Material Safety Data Sheet
Synonym:	1-Phenylcyclohexane-1-carboxylic aci
CAS:	1135-67-7

Section 1 - Chemical Product MSDS Name:1-Phenyl-1-cyclohexanecarboxylic acid 95% Material Safety Data Sheet
Synonym:1-Phenylcyclohexane-1-carboxylic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1135-67-7	1-Phenyl-1-cyclohexanecarboxylic acid	95	214-495-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid contact with skin and eyes. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1135-67-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige - brown
Odor: None reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 121 - 123 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C13H16O2
Molecular Weight: 204.27

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1135-67-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Phenyl-1-cyclohexanecarboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1135-67-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1135-67-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1135-67-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

聚合物和大分子半导体砌块

反应信息

• 作为反应物：
  描述：

  1-苯基-1-环己羧酸 在 lithium aluminium tetrahydride 、 叠氮磷酸二苯酯 、 氧气 、 copper diacetate 、 magnesium sulfate 、 三乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 150.0 ℃ 、101.33 kPa 条件下， 反应 36.0h， 生成 2,3,4,9-四氢-9-甲基-1H-咔唑
  参考文献：
  名称：

  通过氮-自由基4-exo-trig环化反应进行铜催化的有氧[1,3]-氮转移

  摘要：

  在氧气氛（1个大气压）下，由二乙酸铜催化的新型[1,3]-氮自由基转化已被开发出来，用于从α，α-二取代的苄胺中构建各种吲哚衍生物。在该反应中，氧气用作清洁的终端氧化剂，而水是唯一的副产物。在该转化过程中，五个惰性键被裂解，并且在一个罐中构建了两个C-N键和一个C-C双键。这种独特的方法证明了其对生物活性天然产物和药物的后期修饰的广泛应用潜力。机理研究表明，氨基自由基在苯环上的独特的4- exo- trig环化涉及催化循环。

  DOI：

  10.1002/anie.201709894
• 作为产物：
  描述：

  1-苯基-1-环己烷羧酸甲酯 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 1-苯基-1-环己羧酸
  参考文献：
  名称：

  异羟肟酸酯AR-42的手性衍生物有效抑制I类HDAC酶和癌细胞的增殖。

  摘要：

  在多发性骨髓瘤，白血病和淋巴瘤的临床试验中，AR-42是组蛋白脱乙酰基酶（HDAC）的口服活性抑制剂。它几乎没有氢键供体和受体，但是是手性的2-芳基丁酸酯，可能易于消旋。我们报道了非手性AR-42类似物，其包含通过季碳原子连接的环烷基，对人类I类HDAC的效力提高了40倍（例如，JT86，IC 500.7 nM，HDAC1），对五种人类癌细胞系的细胞毒性增加了25倍，而对正常人类细胞的毒性降低了多达70倍。JT86在促进MM96L黑色素瘤细胞中乙酰化组蛋白H4积累方面比racAR-42强9倍。分子模型和结构-活性之间的关系支持四氢吡喃与HDAC1的结合，而四氢吡喃则是对酶表面水的疏水屏蔽。这种有效的I类HDAC抑制剂可在AR-42活跃的疾病（癌症，寄生虫感染，炎性疾病）中显示出益处。

  DOI：

  10.1021/acs.jmedchem.0c00230
• 作为试剂：
  描述：

  4-甲氧基肉桂醛 、 (5E)-7-oxo-7-phenyl-hept-5-enal 在 1-(4-((R)-(naphthalen-1-ylmethoxy)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)quinolin-6-yl)-3-phenylthiourea 、 D-脯氨酸 、 1-苯基-1-环己羧酸 作用下， 以 甲苯 为溶剂， 反应 72.08h， 以45%的产率得到
  参考文献：
  名称：

  可切换模块化设计的有机催化剂催化的多米诺迈克尔/迈克尔反应

  摘要：

  通过使用模块化设计的有机催化剂 (MDO) 研究了( E )-7-aryl-7-oxohept-5-enals 和反式肉桂醛之间的多米诺 Michael/Michael 反应。发现 MDO 的烯胺和亚胺催化模式都是可切换的，并且可以通过使用预催化剂模块和反应条件的适当组合来单独打开和关闭。当开启 MDO 的烯胺和亚胺催化模式时，可以在优化的条件下以良好的收率和立体选择性获得所需的多米诺反应产物。

  DOI：

  10.1039/d1ob01991k

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Oxidation of Primary Alcohols and Aldehydes to Carboxylic Acids via Hydrogen Atom Transfer
  作者：Wen-Yun Tan、Yi Lu、Jing-Feng Zhao、Wen Chen、Hongbin Zhang

  DOI：10.1021/acs.orglett.1c02188

  日期：2021.9.3

  The oxidation of primary alcohols and aldehydes to the corresponding carboxylic acids is a fundamental reaction in organic synthesis. In this paper, we report a new chemoselective process for the oxidation of primary alcohols and aldehydes. This metal-free reaction features a new oxidant, an easy to handle procedure, high isolated yields, and good to excellent functional group tolerance even in the

  伯醇和伯醛氧化成相应的羧酸是有机合成中的基本反应。在本文中，我们报告了一种用于氧化伯醇和醛的新化学选择性工艺。这种无金属反应具有新的氧化剂、易于操作的程序、高分离产率以及即使在易受攻击的仲醇和叔丁烷亚磺酰胺存在下也具有良好至优异的官能团耐受性的特点。
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090018114A1

  公开（公告）日：2009-01-15

  The present application relates to cannabinoid receptor ligands containing compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式(I)化合物的大麻素受体配体，其中A、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS
  申请人：Stewart Andrew O.

  公开号：US20100130558A1

  公开（公告）日：2010-05-27

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L 1 , L 2 , R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中L1、L2、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。

表征谱图